Item 8.01 Other Events.

The Board of Directors of AVAX Technologies, Inc. (the "Company"), after considering the various options available to the Company in light of the Company's financial circumstances, has approved a plan to deregister the Company's common stock under the Securities Exchange Act of 1934, as amended. Upon filing a Form 15 on or about March 30, 2009, the Company's obligation to file certain reports and forms with the Securities and Exchange Commission (the "SEC"), including Forms 10-K, 10-Q and 8-K, will be suspended immediately. The deregistration and termination of the Company's reporting obligations will become effective 90 days after filing, or such shorter period as the SEC may determine. The Company reserves the right to postpone or withdraw such filing at any time prior to its effectiveness without further notice. Although the Company will benefit from cost savings as a result of the deregistration, its financial difficulties will remain largely unchanged, and until such time as the Company is able to obtain additional capital it will continue to operate on a very limited basis.

The Company has determined that it is necessary to take these steps in order to preserve its limited remaining financial resources for the operation of its business. The Company is currently negotiating to raise additional capital or secure revenue sources to fund current operations. However, at this time there can be no assurance that the Company will successfully obtain the required capital or revenues, or, if obtained, the amounts will be sufficient to fund ongoing operations in 2009 or thereafter. The inability to secure additional capital will have a material adverse effect on the Company, including the possibility that the Company would have to sell a portion or all of its assets, cease operations or seek bankruptcy relief.

In addition, due to the current financial circumstances of the Company, the Board of Directors has decided to temporarily suspend enrollment for its ongoing Phase III Registration, MVALDI trial, M-VAX, for Stage IV melanoma patients.

---